A Phase Ii Randomized Study Of Bms-986012, An Anti-Fucosyl-Gm1 Monoclonal Antibody, Plus Carboplatin, Etoposide, And Nivolumab (Nivo) As First-Line (1l) Therapy In Patients With Extensive-Stage Small Cell Lung Cancer (Es-Sclc)
ANNALS OF ONCOLOGY（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要